Sugi Predict

Sugi Predict / Compounds / SCHEMBL1573468

SCHEMBL1573468

SCHEMBL1573468

O=C(C=Cc1ccc(O)cc1)CC(=O)CCc1ccc(O)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKR1B10 O60218 1/20 0.69
▸ AKR1B1 P15121 1/20 0.69
▸ MAOB P27338 1/20 0.69
▸ PTGS2 P35354 1/20 0.69
▸ GLO1 Q04760 1/20 0.69
▸ CAMK2A Q9UQM7 1/20 0.69
▸ BACE1 P56817 13/20 0.65
▸ CA12 O43570 1/20 0.54
▸ CA1 P00915 1/20 0.54
▸ MET P08581 1/20 0.54
▸ CA4 P22748 1/20 0.54
▸ CA6 P23280 1/20 0.54
▸ CA5A P35218 1/20 0.54
▸ CA7 P43166 1/20 0.54
▸ CA9 Q16790 1/20 0.54
▸ CA14 Q9ULX7 1/20 0.54
▸ CA5B Q9Y2D0 1/20 0.54
▸ MMP1 P03956 1/20 0.50
▸ MMP2 P08253 1/20 0.50
▸ MMP9 P14780 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1573466 1.00 AKR1B10 (0.69) AKR1B10AKR1B1MAOBPTGS2GLO1
SCHEMBL13745604 0.93 MAOB (0.59) AKR1B10AKR1B1MAOBPTGS2GLO1
SCHEMBL13746120 0.93 BACE1 (0.61) AKR1B10AKR1B1MAOBPTGS2GLO1
SCHEMBL13311577 0.89 GSK3B (0.65) AKR1B10AKR1B1MAOBPTGS2GLO1
SCHEMBL21998520 0.87 AKR1B10 (0.67) AKR1B10AKR1B1MAOBPTGS2GLO1
SCHEMBL3204597 0.86 BACE1 (0.74) AKR1B10AKR1B1MAOBPTGS2GLO1
SCHEMBL3204616 0.86 BACE1 (0.74) AKR1B10AKR1B1MAOBPTGS2GLO1
Bisdemethoxycurcumin SCHEMBL428638 0.83 AKR1B1 (1.00) AKR1B10AKR1B1MAOBPTGS2GLO1
Bisdemethoxycurcumin SCHEMBL2574140 0.83 AKR1B1 (1.00) AKR1B10AKR1B1MAOBPTGS2GLO1
SCHEMBL17019815 0.83 ABCB1 (0.76) AKR1B1MAOBPTGS2GLO1CAMK2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100048957-A1 METHOD TO PREPARE PURE CURCUMIN KIM DARRICK S H L 2010-02-25 — — US claimed
EP-2037762-A4 METHOD TO PREPARE PURE CURCUMIN KIM DARRICK S H L (US) 2009-07-08 — — EP claimed
EP-2037762-A1 METHOD TO PREPARE PURE CURCUMIN Kim, Darrick S.H.L. (US) 2009-03-25 — — EP claimed
WO-2007143635-A1 METHOD TO PREPARE PURE CURCUMIN KIM DARRICK S (US) 2007-12-13 — — WO claimed
WO-2022090877-A1 METAL COMPLEXES OF DIARYLHEPTANOIDS AND ITS DERIVATIVES ARJUNA NATURAL PRIVATE LIMITED (IN) 2022-05-05 — — WO disclosed
US-10912803-B2 Probiotic and polyphenol against neurodegeneration SOCIETE DES PRODUITS NESTLE S.A. (CH) 2021-02-09 — — US disclosed
US-20180028582-A1 PROBIOTIC AND POLYPHENOL AGAINST NEURODEGENERATION Société des Produits Nestlé S.A. (CH) 2018-02-01 — — US disclosed
US-9801915-B2 Probiotic and polyphenol against neurodegeneration NESTEC S.A. (CH) 2017-10-31 — — US disclosed
US-20170224637-A1 INTRANSAL DELIVERY OF CURCUMIN DePuy Synthes Products, Inc. (US) 2017-08-10 — — US disclosed
US-20160374960-A1 Method of Topically Administering a Curcumin Derivative JOHNSON & JOHNSON CONSUMER, INC. 2016-12-29 — — US disclosed
EP-2863929-B1 PROBIOTIC AND POLYPHENOL AGAINST NEURODEGENERATION NESTEC SA (CH) 2016-07-20 — — EP disclosed
EP-2749552-B1 Curcumin-resveratrol hybrids CODMAN & SHURTLEFF (US) 2015-11-18 — — EP disclosed
EP-2037762-A4 METHOD TO PREPARE PURE CURCUMIN KIM DARRICK S H L (US) 2009-07-08 — — EP disclosed
US-20090087385-A1 Intranasally administering curcumin in a bolus of helium gas to treat alzheimers disease CODMAN & SHURTLEFF, INC. 2009-04-02 — — US disclosed
EP-2037762-A1 METHOD TO PREPARE PURE CURCUMIN Kim, Darrick S.H.L. (US) 2009-03-25 — — EP disclosed
WO-2008131059-A2 INTRANASALLY ADMINISTERING CURCUMIN IN A BOLUS OF HELIUM GAS TO TREAT ALZHEIMER'S DISEASE CODMAN & SHURTLEFF, INC. (US) 2008-10-30 — — WO disclosed
US-20080076821-A1 INTRANASALLY ADMINISTERING CURCUMIN PRODRUGS TO THE BRAIN TO TREAT ALZHEIMER'S DISEASE DePuy Synthes Products, Inc. 2008-03-27 — — US disclosed
WO-2007143635-A1 METHOD TO PREPARE PURE CURCUMIN KIM DARRICK S (US) 2007-12-13 — — WO disclosed
US-20070003641-A1 Synergistic pharmaceutical compositions useful in prevention and treatment of beta-amyloid protein-induced disease KIM DARRICK S H 2007-01-04 — — US disclosed
US-20060148905-A1 Methods for treatment of beta-amyloid protein-induced ocular disease KIM DARRICK S H 2006-07-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160374960-A1 Method of Topically Administering a Curcumin Derivative S100A11, S100A4, S100A6 AKR1B10 554/4885AKR1B1 482/4885MAOB 833/4885
US-20070003641-A1 Synergistic pharmaceutical compositions useful in prevention and treatment of beta-amyloid protein-induced disease APP, BACE1, GSAP AKR1B10 3281/4885AKR1B1 3323/4885MAOB 1411/4885
US-20170224637-A1 INTRANSAL DELIVERY OF CURCUMIN FABP7, FABP2, NDUFB5 AKR1B10 2359/4885AKR1B1 1560/4885MAOB 857/4885
US-20060148905-A1 Methods for treatment of beta-amyloid protein-induced ocular disease APP, CRYAB, BACE1 AKR1B10 2305/4885AKR1B1 2132/4885MAOB 607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.